A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinteics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 through 5 Years with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation